Skip to main content

Day: June 4, 2021

Apollo to Present at Morgan Stanley’s Virtual Financials, Payments and CRE Conference

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”), today announced that James Zelter, Co-President and Chief Investment Officer, Credit, will present at Morgan Stanley’s Virtual Financials, Payments and CRE Conference on Tuesday, June 15, 2021 at 11:45 am ET. A live webcast of the presentation will be available on the Stockholders section of Apollo’s website at https://www.apollo.com/stockholders. For those unable to listen to the live webcast, a replay will be available on Apollo’s website shortly after the event. About ApolloApollo is a high-growth, global alternative asset manager. We seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business...

Continue reading

Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US

Bagsværd, Denmark, 4 June 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy™ is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity. Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist   therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme. Across the trials in people without type 2 diabetes, an average weight loss of 17-18%1 sustained over 68 weeks was reported for people with obesity treated...

Continue reading

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA® (brincidofovir) tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients, including neonates. “We are delighted to report our first FDA approved products for the treatment of smallpox, particularly as the importance of pandemic preparedness has been put into focus over the last year. With this approval in hand, we now look forward to advancing our discussions with the Biomedical...

Continue reading

WillScot Mobile Mini Holdings to Participate in the Baird 2021 Global Consumer, Technology & Services Conference

PHOENIX, June 04, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini Holdings” or the “Company”) (Nasdaq: WSC), a North American leader in turnkey modular space and portable storage solutions, today announced that Brad Soultz, Chief Executive Officer and Tim Boswell, Chief Financial Officer, will be presenting and hosting private meetings during the Baird 2021 Global Consumer, Technology & Services Conference on Tuesday, June 8, 2021. The presentation will take place at 2:35 p.m. Eastern Daylight Time. About WillScot Mobile Mini Holdings WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions....

Continue reading

Proactive news headlines including GreenBank Capital, TRACON Pharmaceuticals, Predictive AI and the Valens Company

New York , June 04, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:GreenBank Capital Inc (CSE:GBC) (OTCPINK:GRNBF) (FRA:2TL) wins ‘Most Innovative Global Merchant Bank’ in Canada award from CFI.co click here GGX Gold Corp (CVE:GGX) (OTCQB:GGXXF) (FRA:3SR2) set to kick off 2021 exploration at its Gold Drop property in British Columbia click here Alpine 4 Holdings Inc (OTCQB:ALPP) subsidiary Alternative Laboratories adds $2M in backlog nutritionals orders click here TRACON Pharmaceuticals Inc (NASDAQ:TCON) presents Phase 1 study data of uliledlimab and atezolizumab at American Society of Clinical Oncology meeting click here Predictiv AI Inc (CVE:PAI) (OTCPINK:INOTF) (FRA:71TA) formalizes ThermalPass relationship...

Continue reading

ABC arbitrage: Activity pace and specific event 2021

ABC arbitrageActivity pace and specific event 2021 Due to the exceptional circumstances related to Covid-19, the Combined General Meeting on Friday, June 11, 2021 will be held behind closed doors. In order to maintain a shareholder debate prior to the votes, a streaming information meeting will be held on June 8, 2021 at 11:00 am. This press release is intended to ensure that the information provided is fair in this specific context. Specific event of the year 2021On June 4, 2021, the Group agreed with the French tax authorities to modify the characteristics of its Transfer Pricing Policy (“TPP”) in order to secure and consolidate its future development capacities. The tax risk set out in our 2019 and 2020 consolidated financial statements (paragraph 3.7 provision for risks and liabilities) is thus definitively extinguished....

Continue reading

HUMBL Announces Completion of Tickeri Acquisition

HUMBL, IncCompletion of Tickeri AcquisitionSan Diego, California, June 04, 2021 (GLOBE NEWSWIRE) — HUMBL, Inc. (OTC Markets: HMBL) today announced that it has completed its acquisition of Tickeri, Inc., a leading Latin-focused ticketing platform. The purchase price for the acquisition was paid with a mix of debt and common stock, for a total of $20M USD. HUMBL will be working to deliver ticketing, peer-to-peer remittances, and mobile pay services to Latin American customers, fitting seamlessly across the existing Tickeri platform and plans for mutual international expansion. “There is an exciting convergence underway across mobile pay, ticketing, and NFTs on blockchain,” said Brian Foote, CEO of HUMBL. “Tickeri has created an outstanding technology platform and loyal audience with whom we are...

Continue reading

ISS Recommends Extended Stay America Shareholders Vote for the Amended Transaction With Blackstone and Starwood Capital

Proxy Advisor Reverses Previous Position, Recommends Increased $20.50 Per Paired Share Merger Price CHARLOTTE, N.C., June 04, 2021 (GLOBE NEWSWIRE) — Extended Stay America, Inc. (“ESA”) and its paired-share REIT, ESH Hospitality, Inc. (“ESH” and, together with ESA, “Extended Stay” or the “Company”) (NASDAQ: STAY) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has reversed its prior voting recommendation. It recommends that Extended Stay shareholders vote FOR the now amended and higher $20.50 per paired share acquisition agreement with a 50/50 joint venture between funds managed by Blackstone Real Estate Partners (“Blackstone”) and Starwood Capital Group (“Starwood Capital”) at the Company’s Special Meetings of Shareholders, which is scheduled to be adjourned to June...

Continue reading

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf” NK Cell-Based Cancer Treatments Rapidly to Patients

SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet (“KI”) in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer (“NK”) cells derived from induced pluripotent stem cells (“iPSCs”). Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (“NextGenNK”) coordinated by KI. Under the agreement, Sorrento will provide know-how in the core chimeric antigen receptor (“CAR”) and dimeric antigen receptor (“DAR”) technologies and...

Continue reading

GTT: Statement of own shares dealings on May 26, 2021 

GAZTRANSPORT & TECHNIGAZSociété anonyme au capital de 370.783,57 eurosSiège social : 1 route de Versailles – 78470 Saint-Rémy-lès-Chevreuse662 001 403 R.C.S. Versailles GTT – Statement of own shares dealings on May 26, 2021                           Aggregate presentation by day and market Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market (MIC Code)GAZTRANSPORT ET TECHNIGA SA 969500BVOHVZUUFWDT54 26/05/2021 FR0011726835 185,392 67.00 XPAR                 TOTAL 185 392    Details transaction per transaction Name Issuer’s identifying code Name of the broker Date Identifying code of financial instrument Price per unit Currency Quantity bought Quantity bought Reference...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.